These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 18549667)

  • 41. Development of novel fast-dissolving tacrolimus solid dispersion-loaded prolonged release tablet.
    Cho JH; Kim YI; Kim DW; Yousaf AM; Kim JO; Woo JS; Yong CS; Choi HG
    Eur J Pharm Sci; 2014 Apr; 54():1-7. PubMed ID: 24388864
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sustained release of highly water-soluble drugs with micelle forming ability from polyionic matrix tablets.
    Tanaka Y; Miyazaki Y; Yakou S; Takayama K
    Pharmazie; 2007 Jan; 62(1):41-5. PubMed ID: 17294812
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Pharmacodynamics of compound danshen pH-dependent delayed release pellets in dogs].
    Yang DL; Yu YL; Tang X; Wan HJ; Song HT
    Yao Xue Xue Bao; 2005 Dec; 40(12):1075-9. PubMed ID: 16496668
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Formulation of sustained - release lithium carbonate matrix tablets: influence of hydrophilic materials on the release rate and in vitro-in vivo evaluation.
    Emami J; Tavakoli N; Movahedian A
    J Pharm Pharm Sci; 2004 Nov; 7(3):338-44. PubMed ID: 15576014
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Preparation of nifidipine pulsatile release tablets].
    Zhang Y; Zhang ZR
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Mar; 35(2):261-3. PubMed ID: 15071935
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human bioavailability of propranolol from a matrix-in-cylinder system with a HPMC-Gelucire core.
    Mehuys E; Remon JP; Korst A; Van Bortel L; Mols R; Augustijns P; Porter C; Vervaet C
    J Control Release; 2005 Oct; 107(3):523-36. PubMed ID: 16055224
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of a reservoir-type transdermal enantioselective-controlled delivery system for racemic propranolol using a molecularly imprinted polymer composite membrane.
    Suedee R; Bodhibukkana C; Tangthong N; Amnuaikit C; Kaewnopparat S; Srichana T
    J Control Release; 2008 Aug; 129(3):170-8. PubMed ID: 18550193
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Colon-specific delivery tablets of sodium 4-aminosalicylic acid.
    Li Y; Li HJ; Yang GR; Gu WP; Ma YK; Zhang MH; Sun J; Sun SJ
    Yao Xue Xue Bao; 2006 Oct; 41(10):927-32. PubMed ID: 17184108
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dissolution studies on tablets of ibuprofen using chitosan.
    Ilango R; Kavimani S; Jaykar B; Umamaheshwari G
    Indian J Exp Biol; 1999 May; 37(5):505-8. PubMed ID: 10492622
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hydrodynamically balanced systems as sustained release dosage forms for propranolol hydrochloride.
    Khattar D; Ahuja A; Khar RK
    Pharmazie; 1990 May; 45(5):356-8. PubMed ID: 2395898
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Once-daily propranolol extended-release tablet dosage form: formulation design and in vitro/in vivo investigation.
    Huang YB; Tsai YH; Yang WC; Chang JS; Wu PC; Takayama K
    Eur J Pharm Biopharm; 2004 Nov; 58(3):607-14. PubMed ID: 15451535
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preparation and in vitro evaluation of a novel combined multiparticulate delayed-onset sustained-release formulation of diltiazem hydrochloride.
    Chen S; Zhu J; Cheng J
    Pharmazie; 2007 Dec; 62(12):907-13. PubMed ID: 18214341
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of novel one-step dry-coated tablets as a platform for delayed-release tablets.
    Ozeki Y; Ando M; Watanabe Y; Danjo K
    J Control Release; 2004 Feb; 95(1):51-60. PubMed ID: 15013231
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation and preparation of controlled release lipid micropheres of sulphamethizole by a congealable disperse phase encapsulation method.
    Yüksel N; Aydmli A; Ozalp Y; Ozdemir N
    Acta Pol Pharm; 2000; 57(3):187-92. PubMed ID: 11143707
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vivo and in vitro evaluation of three controlled release principles of 6-N-cyclohexyl-2'-O-methyladenosine.
    Royce A; Li S; Weaver M; Shah U
    J Control Release; 2004 May; 97(1):79-90. PubMed ID: 15147806
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimization of propranolol HCl release kinetics from press coated sustained release tablets.
    Ali AA; Ali AM
    Pharm Dev Technol; 2013; 18(5):1238-46. PubMed ID: 22582904
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Different HPMC viscosity grades as coating agents for an oral time and/or site-controlled delivery system: a study on process parameters and in vitro performances.
    Sangalli ME; Maroni A; Foppoli A; Zema L; Giordano F; Gazzaniga A
    Eur J Pharm Sci; 2004 Aug; 22(5):469-76. PubMed ID: 15265517
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design and evaluation of sustained release bilayer tablets of propranolol hydrochloride.
    Patra CN; Kumar AB; Pandit HK; Singh SP; Devi MV
    Acta Pharm; 2007 Dec; 57(4):479-89. PubMed ID: 18165191
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro and in vivo evaluations of a novel pulsed and controlled osmotic pump capsule.
    Zhang W; Zhang L; Qu X; Zhu Z; Pan Y; Guan J; Pan W
    Drug Dev Ind Pharm; 2015 Feb; 41(2):322-32. PubMed ID: 24295490
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Colonic release and reduced intestinal tissue damage of coated tablets containing naproxen inclusion complex.
    Piao ZZ; Lee MK; Lee BJ
    Int J Pharm; 2008 Feb; 350(1-2):205-11. PubMed ID: 17928177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.